cyrilzakka/clinical-trials huggingface dataset:
Application of 3D Visualization and 3D Printing in the Hepatobiliary and Pancreatic Surgery

Background:The aim of the study is to value the application of three-dimensional visualization and three-dimensional printing in the hepatobiliary and pancreatic surgery.Method：From January 2016 to December 2018,the clinical data of 200 patients with the hepatobiliary and pancreatic diseases will be collected.All the patients received abdominal CT scanning and 3D reconstruction. Then we used the 3D reconstruction model and the 3D printed model based on the 3D reconstruction model in the operation planning and the operation.The clinical data include operative time, intraoperative blood loss,and postoperative complications after surgery.

From January 2016 to December 2018,the clinical data of 200 patients with the hepatobiliary and pancreatic diseases will be collected.All the patients received abdominal CT scanning and 3D reconstruction. Then we used the 3D reconstruction model and the 3D printed model based on the 3D reconstruction model in the operation planning and the operation.The clinical data include operative time, intraoperative blood loss,and postoperative complications after surgery.

Eligibility Criteria:
Inclusion Criteria:

* the hepatobiliary and pancreatic diseases

Exclusion Criteria:

* none of the hepatobiliary and pancreatic diseases
A Clinical Registry of Orthobiologics Procedures

The purpose of the Registry study is to observe the improvement in subject-reported clinical outcomes for percutaneous orthopedic procedures for treatment of musculoskeletal disorders.

This Registry was designed to assure that the benefits and knowledge gained by studying clinical outcomes associated with the use of percutaneous orthopedic procedures outweigh the potential risks to the patients. The primary objective of this Registry is to observe the improvements in subject-reported clinical outcomes for these procedures used to treat musculoskeletal disorders. Secondary objectives include evaluating post-treatment complication, adverse events, re-injections, and surgical intervention. Patients receiving percutaneous orthopedic treatments are asked to enroll before receiving treatment and complete a set of baseline questionnaires regarding pain and functionality of the area of the body being treated (i.e. knee, shoulder, spine, etc). Follow-up outcomes are collected at 1 month, 3 months, 6 months, 12 months, 18 months, and annually 2-20 years post-injection. Subjects are withdrawn from the Registry prematurely if a surgical operation occurs.

Eligibility Criteria:
Inclusion Criteria:

* Candidates must meet ALL of the following:

  1. Voluntary signature of the IRB approved Informed Consents,
  2. Treated with a Regenexx procedure
  3. Have a musculoskeletal condition appropriate for the procedure such as osteoarthritis or internal joint derangement; ligament or tendon injury; intervertebral disc degeneration; protrusion, extrusion, or annular tear; muscle tear

Exclusion Criteria:

* none
Effectiveness and Safety of Salba on Weight Loss in Overweight Individuals With Type 2 Diabetes

Canadian statistics indicate that the incidence of obesity is increasing and that the occurrence of diabetes in obese individuals is 5-fold greater than those with a healthy weight, making weight control in this population particularly relevant. Preliminary clinical data has shown that the whole grain, Salba, may improve type 2 diabetes control, reduce after-meal blood glucose, cardiovascular disease (CVD) risk factors and suppress appetite. Its use may therefore have potential implications in long-term weight management, while improving diabetes.

The objective of this research (weight loss) is to evaluate whether adding Salba to an energy reduced diet for six months will result in greater weight loss compared to control in overweight and obese individuals with type 2 diabetes. The study recruited 77 overweight or obese individuals with type 2 diabetes. They were instructed to follow a calorie restricted diet and their regular diabetes therapy together with regular exercise. Participants were randomly assigned to receive 30 g Salba/1000 kcal of daily energy requirements, or an oat bran control supplement matched for energy. The effect of the supplements on weight-loss (including waist circumference, % body fat) and glucose control (A1c, fasting glucose levels) will be assessed. In addition, related outcomes such as low-grade body inflammation, hunger-regulating hormones (ghrelin, adiponectin), safety measures (urea, creatinine, ALT and prothrombin time) and satiety scores were evaluated.

Modest weight loss has been associated with improved glucose control in individuals with type 2 diabetes. Addition of Salba to an energy reduced diet may facilitate greater weight loss and improve glycemic control and CVD risk factors compared to such a diet alone. Salba may also promote maintenance of weight loss and therefore help prevent weight gain by providing feelings of fullness that reduce appetite. In light of the high incidence of obesity in individuals with diabetes, Salba grain may be a useful addition to the diet.


Eligibility Criteria:
Inclusion Criteria:

* Well-controlled type 2 diabetes for at least 1 year
* Treated with diet and/or oral hypoglycemic medications
* BMI 25-40 kg/m2

Exclusion Criteria:

* Weight change in the past three months \>10% of body weight
* On insulin therapy
* Unstable angina, myocardial infarction or stroke (within 6 months)
* Planned surgery or pregnancy
* Blood pressure \>160mmHg/100mmHg
* Surgical procedures for weight loss and concomitant use of medication or supplements that alter body weight or appetite
* ALA, dietary fibre, fish oil supplements or consuming cold-water fish more than three times per week
Using Vedolizumab-800CW to Gain Insight Into Local Drug Distribution and Mucosal Target Cells in IBD Patients

Summary Vision Study

Crohn's Disease (CD) and Ulcerative Colitis (UC) are chronic idiopathic inflammatory bowel diseases (IBD). Vedolizumab is a humanized monoclonal antibody against α4β7 integrin, capable of blocking the migration of several immune cells across endothelium expressing MAdCAM-1. Vedolizumab is expensive and primary non-response is high in both CD and UC. Currently there are no predictors of response to vedolizumab and the actual mechanism of action has not yet been elucidated. To clarify the mechanism of action and gain better understanding of the high primary non-response rates, the University Medical Center Groningen (UMCG) developed a tracer fluorescently labeling vedolizumab. This study aims to gain insight into vedolizumab distribution and concentrations in the gut. The current study aims to identify the vedolizumab target cells in the inflamed gut mucosa using quantitative fluorescence molecular imaging (FMI). By gaining insight into local vedolizumab concentrations, drug distribution and by discovering target cells, we expect to gain insight into the mechanism of action of vedolizumab.


Eligibility Criteria:
Inclusion Criteria:

* Established diagnosis of IBD, or Ulcerative Colitis (UC) or Crohn's Disease (CD).
* Vedolizumab naïve and eligible for vedolizumab treatment.
* Age: 18 years or older.
* Written informed consent.

Exclusion Criteria:

* Prior vedolizumab treatment
* Vedolizumab contraindicated as therapy
* Pregnancy or breast feeding.
* Patients younger than 18 years old
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

This trial will evaluate safety and efficacy of BI 10773 in hypertensive patients with type 2 diabetes. Since hyperglycaemia and hypertension are key risk factors for both micro- and macrovascular complications, assessment of both glucose and blood pressure lowering effects of BI 10773 in hypertensive patients with type 2 diabetes could provide clinically highly relevant, new information for the use of BI 10773


Eligibility Criteria:
Inclusion criteria:

1. Patients \>=18 years with type 2 diabetes
2. HbA1c of \>= 7.0% (53 mmol/mol) and =\< 10% (86 mmol/mol)
3. Mean seated systolic blood pressure 130-159 mmHg and diastolic blood pressure 80-99 mmHg

Exclusion criteria:

1. Uncontrolled hyperglycaemia with a glucose level \>240 mg/dl (\>13.3 mmol/L) after an overnight fast before randomization
2. Known or suspected secondary hypertension
3. Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris), stroke or transient ischemic attack within 3 months prior to informed consent
Breast Cancer Registry - National University Health System, Singapore

The Breast Cancer Registry aims to collect clinical data of all breast cancer patients diagnosed and/or treated in the National University Hospital, with the goal of understanding risk factors, presenting symptoms, diagnosis, treatment, and outcome data of breast cancer in Singapore. This information will contribute to improving management of breast cancer patients.


Eligibility Criteria:
Inclusion Criteria:

- All breast cancer patients who were diagnosed or managed in NUH.

Exclusion Criteria:

- Non breast cancer patients.
Investigation of the Relationship Between Dysfunctional Breathing and Physical Fitness Parameters in Healty Adults

This observational study aims to investigate the relationship between dysfunctional breathing and physical fitness parameters in healthy adults aged 18-35. Participants will be evaluated using the Nijmegen Questionnaire to assess dysfunctional breathing symptoms, and their physical fitness will be measured using the ALPHA-FIT Test Battery. Respiratory muscle strength and pulmonary function will also be assessed. The findings may help healthcare professionals better understand dysfunctional breathing and develop targeted treatment programs.

Dysfunctional breathing (DB) is characterized by chronic alterations in the respiratory cycle, often leading to symptoms such as dyspnea, chest tightness, and hyperventilation. Despite its prevalence, DB is frequently underdiagnosed and mismanaged due to limited awareness among healthcare professionals. This cross-sectional study aims to evaluate the relationship between DB symptoms and physical fitness in healthy young adults. A total of 38 participants diagnosed with DB will be assessed at Istinye University using the Nijmegen Questionnaire, ALPHA-FIT Test Battery, spirometry, and measurements of maximum inspiratory (MIP) and expiratory (MEP) mouth pressures. Data on sociodemographic characteristics will also be collected. The results of this study are expected to support clinicians in the accurate identification of DB and provide insight for the development of personalized rehabilitation strategies that improve physical fitness and respiratory health.

Eligibility Criteria:
Inclusion Criteria:

* Aged between 18-35 years
* Healthy individuals with no known systemic, neurological, or musculoskeletal disorders
* Nijmegen Questionnaire score \>23 (indicative of dysfunctional breathing)
* Voluntary participation with informed consent

Exclusion Criteria:

* Diagnosed with respiratory, cardiovascular, or metabolic disease
* Currently receiving physiotherapy or pulmonary rehabilitation
* Regular use of medication affecting breathing or exercise capacity
* Pregnancy
Depressive Symptoms Among Medical Students

Depression is a common mental disorder, people with depression feel sadness anxious, loss of interest or pleasure, hopeless, helpless, worthless feelings of guilt and poor concentration. It can impair person's ability to function at work or school, or cope with daily life. It can lead to suicide.

Depressive symptoms are higher among women and its prevalence among university students was reported to be higher than the general population .There are various risk factors of depressive symptoms among university students, lower socioeconomic status, poor academic performance, overweight, life stressors, family history of psychiatric disorders, sleeping problems, and exposure to patients' suffering. Several studies were conducted among medical students in different Egyptian Universities to detect prevalence of depressive symptoms which were 42.9% in Al-Azhar Uni-versity, Cairo, 60.8% in Fayoum University, 59.2% in Mansoura University and 57.9% in Alexandria University.

A sense of control means having a feeling of autonomy, of choosing how you spend your time, of doing your own work in your own way, which is a key component of happiness. Depressive symptoms more common in those who feel there is little they can do to change important things in their lives.

Medical education is considered stressful. Medical students have psychological and academic stressors during their revolution from insecure students to young knowledgeable physicians, which were determined to be associated with depressive symptoms and decrease the quality of life and academic achievements.

Eligibility Criteria:
Inclusion Criteria:

All Egyptian medical students at faculty of Medicine, Assiut University in the academic year 2018-2019

Exclusion Criteria:

Non-Egyptian medical students
The Healthy Eating with APP TechnologY Study

The aim of this study is to investigate the effect of using new app-based technology to improve dietary habits, compared to usual care in patients with type 2 diabetes. The hypothesis is that the intervention, i.e. using the new technology an an app-based course for healthy eating habits, will have a greater positive effect on dietary habits and biological markers, including HbA1c and serum lipids, than usual care.


Eligibility Criteria:
Inclusion Criteria:

* Have a diagnosis of type 2 diabetes
* 18 years of age or older
* Ability to communicate in Swedish
* Own and use a smartphone with a personal digital ID

Exclusion criteria:

- No specific exclusion criteria apply
LIFUP for Treatment of Motor Deficits in Parkinson&#39;s Disease

The study will test the feasibility of using Low Intensity Focused Ultrasound Pulsation (LIFUP) to treat motor symptoms in Parkinson's Disease (PD). LIFUP is a new technique that can increase brain activity in highly specific target areas and is MRI compatible. Thus, in real-time, it is possible to directly observe how LIFUP changes the brain areas important in PD by measuring its effects on brain activity, blood flow, and brain connectivity. If successful, this research will mark the first step towards a novel, non-invasive, non-medication treatment for PD.

This trial is a proof-of-concept, proof-of-mechanism study of a novel neuromodulation technology - LIFUP - to treat motor symptoms in PD. Much like Deep Brain Stimulation, LIFUP can be focused on deep brain structures with high spatial accuracy, including those implicated in PD; however, it can do so non-invasively. Other non-invasive neuromodulation tools such as Transcranial Magnetic Stimulation can only target surface brain structures and are not optimal PD treatment tools. This study will test this new technology in 30 participants with PD during simultaneous resting state functional MRI, and collect pre- and post-LIFUP functional MRI, arterial spin labeling, motor performance data, and behavioral data, in a double-blind crossover trial to determine whether LIFUP: 1) will improve motor symptoms during and after treatment; 2) can modulate neural activity in the target brain region important for PD, the internal globus pallidus; and 3) enhance cortico-striatal motor circuit connectivity. All participants in this study will receive active ultrasound at one of the two in-person sessions and sham at the other.

Eligibility Criteria:
Inclusion Criteria:

1. Diagnosis of Parkinson's disease
2. Age 18-85
3. Fluent in the English language

Exclusion Criteria:

1. Metal implants that are not MR compatible
2. Neurological diagnosis other than Parkinson's
3. Not fluent in the English language
Drinking in Young Adult Duos (DYAD) Study

This study examines the role of alcohol use in understanding the dynamics of romantic relationships. Couples will participate in a research session where they consume either an alcoholic or non-alcoholic beverage and complete study tasks. After the session, participants will provide information about their drinking habits, alcohol- and non-alcohol-related experiences, and relationship factors through brief surveys on their smart phones and again at 6-month and 12-month follow-up sessions. The findings from this study aim to improve understanding of alcohol use in close relationships and may inform future strategies for promoting healthier relationships and behaviors.

This study investigates alcohol consumption in romantic relationships. Couples will be recruited to participate in a laboratory-based alcohol administration session, during which they will consume either a moderate dose of alcohol or a non-alcoholic beverage. Following beverage consumption, couples will complete questionnaires and tasks.

The study employs a multi-method approach to assess alcohol in couples, including self-reports and behavioral tasks, both inside and outside of the lab (e.g., using ecological momentary assessment). Additionally, participants' drinking patterns and relationship factors will be tracked over time, with follow-up assessments conducted at 6-months and 12 months post-laboratory session.

The findings from this research will provide insights into the role that alcohol consumption plays in close relationships and may inform interventions to support healthier drinking behaviors and relationship outcomes.

Eligibility Criteria:
Inclusion Criteria:

Both members of the couple must:

* be between the ages of 21 and 30
* regularly consume alcohol
* own a smartphone

Exclusion Criteria:

Neither member of the couple:

* has a history of adverse reaction to the amount of beverage used in the study
* has a history of major problems related to alcohol
* is taking medications that could adversely interact with alcohol
* is pregnant
A Novel Myocardial Impedance Mapping System for Ablation of Post-infarction Ventricular Arrhytmias in Humans

Precise identification of the infarct scar is essential for successful catheter ablation of ventricular arrhythmias in patients with chronic myocardial infarction. Voltage mapping of endocardial electrograms is currently used to delineate the necrotic scar but this is influenced by the direction of the activation wave front and is not sensitive enough to differentiate distinct degrees of transmural injury in the scar. Mapping of local myocardial electrical impedance may overcome these limitations.

Clinical series: Patients with chronic infarction undergoing catheter ablation of ventricular arrhythmias will be submitted to mapping of both voltage and tissue impedance. Likewise, the accuracy of the two maps identifying the extent and transmurality of the infarction will be assesssed by gadolinium imaging. The impedance system is already constructed and certified for clinical research use.

Eligibility Criteria:
Inclusion Criteria:

* More than 18 yearts
* Chronic myocardial infarction
* Undergoing ventricular ablation of ventricular arrhythmias

Exclusion Criteria:

* patients with device not suitable for cardiac magnetic ressonance (CMR)
* pregnacy
Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322)

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of multiple autoantibodies and accumulation of immune complexes resulting in systemic inflammatory response and tissue damage.

Dysfunction of proteins initially known to initiate the classical pathway for complement activation (C1q and C1s), and their functional interference with the multifunctional protein HMGB1 (High-Mobility Group Box 1), appears to be associated with SLE. On the other hand, C1s, HMGB1 and C1q can be targeted by anti-C1s, anti-HMGB1 and anti-C1q autoantibodies from lupus patients, whose functional impact remains to be explored, in particular for non-canonical functions, independent of the complement activation cascade.

Studies are needed to investigate the pathogenic role of these autoantibodies in SLE, including possible interference with the inactivation of HMGB1.

This project plans to investigate the role of anti-C1s, anti-HMGB1 and anti-C1q autoantibodies in the pathogenesis of Systemic Lupus Erythematosus. This pilot study will be performed for 30 patients with active SLE on serum, realized for routine patient care. The investigators will identify the molecular targets recognized by anti-C1s, anti-HMGB1 and anti-C1q autoantibodies purified from the SLE patients' serum. The investigators will also explore the functional role of these purified autoantibodies.

Regarding the exploration of anti-C1s autoantibodies purified from the SLE patients' serum, the investigators will evaluate their effects on the formation of the C1r2C1s2 tetramer and interaction with C1q and their effects on the esterase activity of C1s.

Regarding the exploration of anti-HMGB1 autoantibodies purified from the SLE patients' serum, the investigators will evaluate their effects on the binding of HMGB1 to its RAGE receptor and their effects on the binding of HMGB1 to C1q.

Regarding the exploration of anti-C1q autoantibodies purified from the SLE patients' serum, the investigators will evaluate their effects on the binding of C1q to its receptors and to the C1r2C1s2 tetramer and their effects on the activation of the classical Complement pathway.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years old
* Weight ≥ 40 Kg
* Patients who have valid health insurance
* Patients with lupus diagnosis criteria (EULAR-ACR-2019)
* Active lupus nephritis defined by SLEDAI score \>5 and joint and/or kidney involvement.

Exclusion Criteria:

* Patient protected by law (minors, pregnant or breastfeeding women, subject under guardianship or curatorship, deprived of liberty or enforced hospitalized, under administrative or judicial supervision).
* Patient on dialysis or on plasma exchange.
Reduction in Spinal-induced Hypotension With Ondansetron in Parturients Undergoing Caesarean Section

Subarachnoid block is the preferred method of anaesthesia for caesarean section, but is associated with hypotension and bradycardia, which may be deleterious to both parturient and baby. Animal studies suggest that in the presence of decreased blood volume, 5-HT may be an important factor inducing the Bezold Jarisch reflex via 5-HT3 receptors located in intracardiac vagal nerve endings. In this study, the investigators evaluated the effect of ondansetron, as a 5-HT3 receptor antagonist, on the haemodynamic response following subarachnoid block in parturients undergoing elective caesarean section.


Eligibility Criteria:
Inclusion Criteria:

* Undergoing an elective lower segment caesarean section.

Exclusion Criteria:

* Patients with contraindications to subarachnoid block (patient refusal, unstable haemodynamics, coagulation abnormality),
* History of hypersensitivity to ondansetron or local anaesthetic agents,
* Hypertensive disorders of pregnancy,
* Cardiovascular insufficiency,
* Receiving selective serotonin reuptake inhibitors or migraine medications.